diethylamine salicylate
Diethylamine salicylate is a salicylic acid salt, that is a cost-effective and simple, first-line treatment for rheumatic and minor musculoskeletal conditions including lumbago, fibrositis, sciatica, bruises, and strains. Salicylic acid directly and irreversibly inhibits the activity of both types of cyclo-oxygenases (COX-1 and COX-2) to decrease the formation of precursors of prostaglandins and thromboxanes from arachidonic acid. Salicylate's antirheumatic (nonsteroidal anti-inflammatory) actions are a result of its analgesic and anti-inflammatory mechanisms. — NCATS
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Earliest trial started Oct 1, 2013 (NCT02346058)
Timeline
No events for the selected filters.
Indications
Approved for
Mechanism of action
- CyclooxygenaseINHIBITOR
Cyclooxygenase inhibitor
Chemistry & pharmacology
SMILES
CCNCC.OC(=O)C1=C(O)C=CC=C1- Mol. weight
- 211.2576 g/mol
Oral
No
Parenteral
No
Topical
No
Sources
- NCATS5V7PT38BJU ↗
Also known as
- esarin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02346058 | Phase 4 | Oct 1, 2013 | Taichung Veterans General Hospital, Ten Sun Pharma Company Limited |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Taichung Veterans General Hospital | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Ten Sun Pharma Company Limited | For profit | 1 | 1 | 1 | 2013 |